Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adalimumab + hydroxychloroquine + leflunomide + methotrexate
- Development stage
- Preclinical
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Subcutaneous, Intramuscular
01
Overview
This is a combination therapy used for rheumatoid arthritis (RA) that includes a biologic DMARD (adalimumab) and three conventional DMARDs (hydroxychloroquine, leflunomide, and methotrexate). This combination aims to control disease activity, reduce joint damage, and improve symptoms in patients with rheumatoid arthritis. Methotrexate serves as the anchor drug in this combination, with adalimumab (a TNF inhibitor) providing additional anti-inflammatory effects, while hydroxychloroquine and leflunomide work through different mechanisms to further suppress disease activity.
02
Targets
DHFR (Dihydrofolate reductase)DHODH (Dihydroorotate dehydrogenase (quinone), mitochondrial)TLR7 (Toll-like receptor 7)TNFA (Tumor necrosis factor alpha (soluble))CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on adalimumab + hydroxychloroquine + leflunomide + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adalimumab + hydroxychloroquine + leflunomide + methotrexate.